Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EBITDA: 2019-2025

Historic EBITDA for Benitec Biopharma (BNTC) over the last 7 years, with Jun 2025 value amounting to -$37.9 million.

  • Benitec Biopharma's EBITDA fell 86.90% to -$8.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$37.9 million, marking a year-over-year decrease of 73.58%. This contributed to the annual value of -$37.9 million for FY2025, which is 73.58% down from last year.
  • According to the latest figures from FY2025, Benitec Biopharma's EBITDA is -$37.9 million, which was down 73.58% from -$21.8 million recorded in FY2024.
  • In the past 5 years, Benitec Biopharma's EBITDA ranged from a high of -$13.4 million in FY2021 and a low of -$37.9 million during FY2025.
  • Moreover, its 3-year median value for EBITDA was -$21.8 million (2024), whereas its average is -$26.3 million.
  • Data for Benitec Biopharma's EBITDA shows a maximum YoY crashed of 73.58% (in 2025) over the last 5 years.
  • Yearly analysis of 5 years shows Benitec Biopharma's EBITDA stood at -$13.4 million in 2021, then plummeted by 34.47% to -$18.0 million in 2022, then dropped by 6.38% to -$19.1 million in 2023, then fell by 13.92% to -$21.8 million in 2024, then plummeted by 73.58% to -$37.9 million in 2025.